Immune checkpoint proteins play a central role in regulating the activities of different immune cell types. These molecules have either stimulatory functions that promote immune cell activation to protect the host from invading pathogens and developing malignancies, or inhibitory functions that suppress immune cell activation to dampen inflammation, maintain immune homeostasis, and prevent tissue damage. Tumor cells frequently exploit immune checkpoint pathways by up-regulating the expression of ligands that activate inhibitory receptors on different immune cell types, allowing them to evade destruction by the host’s immune system. As a result, researchers have focused on targeting immune checkpoint molecules for cancer immunotherapy using either agonists of immune cell stimulatory receptors to drive immune cell activation or antagonists of inhibitory receptors to promote immune checkpoint blockade. While remarkable success has been achieved by targeting the T cell co-inhibitory receptors, CTLA-4 and PD-1, clinicians have also found that monoclonal antibodies directed against CTLA-4, PD-1, or the PD-1 ligand, PD-L1, are only effective in a minority of cancer patients and some patients that initially respond to treatment with these antibodies, can become resistant or relapse due to an up-regulation of other immune checkpoint pathways. Therefore, additional immune checkpoint regulators that may serve as immunotherapeutic targets, either alone or in combination, are being sought.
Immune Checkpoint Protein Targets
B7-CD28 Families
B7-CD28 Families
Members of the B7 family of immune checkpoint proteins bind to receptors belonging to the CD28 family and promote or inhibit T cell activation following antigenic peptide/MHC recognition by the TCR. The B7 and CD28 families include the immune checkpoint proteins, PD-L1, PD-1, and CTLA-4, which are some of the most highly investigated targets for cancer immunotherapy.
Butyrophilins
Butyrophilins
Butyrophilins are T cell co-inhibitory/co-stimulatory molecules that are structurally related to the B7 family of immune checkpoint proteins and appear to have similar immunomodulatory functions. For these reasons, they are currently being investigated as potential next generation immune checkpoint targets.
CD47-SIRP Pathway
CD47-SIRP Pathway
The SIRP/CD47 pathway is an innate immune checkpoint that suppresses the phagocytic activity of myeloid cells. CD47 is overexpressed in a variety of hematologic and solid tumor cancers, indicating that tumor cells may exploit this pathway to evade phagocytic destruction.
Kynurenine Pathway
Kynurenine Pathway
Depletion of tryptophan and kynurenine production by the kynurenine pathway can inhibit the functions of T cells and natural killer cells and promote the generation of regulatory T cells. As tumor cells or cells in the tumor microenvironment can express high levels of IDO and TDO2, two key enzymes that catalyze the initial and rate-limiting step in this pathway, inhibitors of these molecules are being investigated as potential immunotherapeutic drugs.
LAG-3
LAG-3
LAG-3 is an inhibitory immune checkpoint receptor that negatively regulates T cell activity and promotes the suppressive activity of regulatory T cells. This receptor is up-regulated on exhausted T cells and natural killer cells in cancer and is thought to contribute to their dysfunction, making it a target for immuno-oncology researchers.
LILRB Receptor Family
LILRB Receptor Family
Members of the LILRB subfamily are immune checkpoint receptors that can inhibit the functions of multiple immune cell types following activation. These receptors and their ligands are being investigated by immuno-oncology researchers as they can be up-regulated on tumor cells or immune cells present in the tumor microenvironment, allowing tumors to evade immune detection.
TIGIT, DNAM-1, CD96, and PVRIG
TIGIT, DNAM-1, CD96, and PVRIG
TIGIT, DNAM-1, CD96, and PVRIG are immune checkpoint receptors that share CD155/PVR and/or CD112/Nectin-2 as ligands, but mediate opposing effects on lymphocyte functions. While DNAM-1/CD226 acts as a co-stimulatory receptor, TIGIT, PVRIG, and CD96 function as co-inhibitory receptors on T cells and natural killer cells. As a result, these proteins are being explored as targets for cancer immunotherapy.
TIM-3
TIM-3
High level expression of TIM-3 on CD8+ T cells and natural killer cells is associated with an exhausted phenotype, and its expression on tumor-associated FoxP3+ regulatory T cells (Tregs) marks a subset of Tregs with enhanced suppressor functions and increased resiliency. Due to these characteristics, immuno-oncology researchers are investigating TIM-3 blockade to determine if they can improve anti-tumor immune responses.
TNF Receptor Superfamily Co-Stimulatory Molecules
TNF Receptor Superfamily Co-Stimulatory Molecules
As an alternative to immune checkpoint blockade to restore anti-tumor immune responses, agonists of co-stimulatory immune checkpoint receptors are also being explored. Many of these receptors belong to the TNF receptor superfamily and have been shown to be involved in enhancing the proliferation and effector functions of T cells and/or natural killer cells.
R&D Systems Immune Checkpoint Proteins Are Rigorously Tested to Ensure Lot-to-Lot Consistency
R&D Systems Recombinant Human PD-1 Displays High Lot-to-Lot Consistency. Two independent lots of Recombinant Human PD-1 (R&D Systems, Catalog # 8986-PD) immobilized at 1 ug/mL were tested for their ability to bind to increasing concentrations of Recombinant Human PD-L1/B7-H1 Fc Chimera (R&D Systems, Catalog # 156-B7) in a functional ELISA. The concentration of Recombinant Human PD-L1/B7-H1 Fc Chimera that produces 50% of the optimal binding response is approximately 0.3-1.8 ug/mL. Each trace on the graph represents data obtained from Recombinant Human PD-1 from a different manufacturing run, demonstrating the lot-to-lot consistency of the protein.
Protein Characterization Using SEC-MALS Analysis
Recombinant Human PD‑1 Fc Chimera Protein SEC-MALS. Recombinant human PD-1/Fc (Catalog # 1086-PD) has a molecular weight (MW) of 125.1 kDa as analyzed by SEC-MALS, suggesting that this protein is a homodimer. MW may differ from predicted MW due to post-translational modifications (PTMs) present (i.e. Glycosylation).
SEC-MALS Data | Result |
Retention Time | 14.7-15.2 min |
MW-Predicted (Monomer) | 42.6 kDa |
MW-MALS | 125.1 kDa |
Polydispersity | 1.001 |
System Suitability: BSA Monomer 66.4 ± 3.32 kDa | Pass |
Analysis of the Binding Properties of R&D Systems Avi-tag Biotinylated Immune Checkpoint Proteins
Affinity Measurements and Binding Kinetics of the CD155/PVR:TIGIT Protein Interaction by Surface Plasmon Resonance. Sensorgram data of captured Avi-tag Biotinylated Recombinant Human CD155/PVR Fc Chimera (R&D Systems, Catalog # AVI9174) binding to Recombinant Human TIGIT His-tag (R&D Systems, Catalog # 9525-TG). The corresponding overlaid kinetic fits with the residual plot shown below. The concentration of Recombinant Human TIGIT His-tag ranged from 0.2 nM to 400 nM. The corresponding steady state affinity fit is shown at the bottom. The experiment was performed on a Biacore T200, GE Healthcare.
Affinity Measurements and Binding Kinetics of the PD-1:PD-L1 Interaction by Surface Plasmon Resonance. Sensorgram data of captured Avi-tag Biotinylated Recombinant Human PD-L1 His tag (R&D Systems, Catalog # AVI9049) binding to Recombinant Human PD-1 His tag (R&D Systems, Catalog # 8986-PD). The corresponding overlaid kinetic fits with the residual plot shown below. The concentration of Recombinant Human PD-1 His-tag ranged from 3.2 nM to 13.2 μM. The corresponding steady state affinity fit is shown below. The experiment was performed on a BiacoreT200, GE Healthcare.
Affinity Measurements and Binding Kinetics of the CTLA-4:B7-1 Interaction by Surface Plasmon Resonance. Sensorgram data of captured Avi-tag Biotinylated Recombinant Human CTLA-4 Fc Chimera (R&D Systems, Catalog # AVI7268) binding to Recombinant Human B7-1 Fc Chimera (R&D Systems, Catalog # 10133-B1). Briefly, Avi-tag Biotinylated Recombinant Human CTLA-4 Fc Chimera was captured at a low coupling density to the active flow cell via the Avi-tag biotin. Recombinant Human B7-1 Fc Chimera at a concentration range between 82 pM and 21 nM was flowed over both active and uncoupled reference flow cells at each concentration. Kinetic sensorgrams were fit to a 1:1 binding model to determine the binding kinetics and affinity, with an interaction affinity of KD=0.2511 nM. The corresponding overlaid kinetic fits with the residual plot shown below. The corresponding steady state affinity fit is shown at the bottom. The experiment was performed on a Biacore T200, GE Healthcare.
Affinity Measurements and Binding Kinetics of the CD47:SIRP alpha Interaction by Surface Plasmon Resonance. Sensorgram data of captured Avi-tag Biotinylated Recombinant Human CD47 Fc tag (R&D Systems, Catalog # AVI4670) binding to Recombinant Human SIRP alpha His tag (R&D Systems, Catalog # 9378-SA). The corresponding overlaid kinetic fits with the residual plot shown below. The concentration of Recombinant Human SIRP alpha His-tag ranged from 6.85 nM to 3.51 μM. The corresponding steady state affinity fit is shown at the bottom. The experiment was performed on a Biacore T200, GE Healthcare.
Related Products for Immune Checkpoint Research
Maurice™ CE-SDS for Evaluating Protein Purity
Maurice™ CE-SDS for Evaluating Protein Purity
Although still used in the industry for protein purity analysis, SDS-PAGE is self-limiting in terms of sensitivity, reproducibility, and its semi-quantitative nature. As an alternative, we offer the fully automated Maurice capillary electrophoresis (CE)-SDS system.This application note outlines the advantages of using Maurice over standard SDS-PAGE analysis for protein purity characterization. Read more on our Protein Simple website.
RNAscope™ In Situ Hybridization Assays
RNAscope™ In Situ Hybridization Assays
RNAscope technology enables the rapid and efficient detection of the co-expression profiles of any target mRNAs, including immune checkpoint targets and immune cell markers, with single-molecule sensitivity and high specificity in formalin-fixed, paraffin-embedded (FFPE) tissues. This technology can be combined with immunohistochemistry or immunofluorescence on the same slide for detecting target RNAs and proteins simultaneously.
Proteins for Immune Cell Culture
Proteins for Immune Cell Culture
Achieve robust, reproducible immune cell cultures with R&D Systems™ proteins. Our proteins are rigorously tested to ensure that they will provide superior performance and lot-to-lot consistency, so you can have confidence in their ability to promote optimal immune cell expansion and differentiation with minimal variability between cultures. To meet your needs from basic research to clinical applications, we offer research-grade, Animal-free RUO, and Animal-free GMP-grade proteins.
Avi-tag Biotinylated Proteins for Immune Checkpoint Targets
Avi-tag Biotinylated Proteins for Immune Checkpoint Targets
Biotinylated proteins can be powerful tools for assessing protein-protein interactions or screening antibody or small molecule libraries for potential therapeutics. We now offer a wide assortment of Avi-tag biotinylated recombinant proteins for immune checkpoint targets.
Fluorokines™ for Immune Checkpoint Ligands
Fluorokines™ for Immune Checkpoint Ligands
Take advantage of our fluorescent-labeled immune checkpoint ligands to easily identify or sort cells expressing the corresponding immune checkpoint receptors. Fluorescent-labeled ligands allow cells expressing their cognate receptors to be stained in a single step and detected by flow cytometry.
Flow Cytometry-Validated Antibodies for Identifying Immune Cell Types
Flow Cytometry-Validated Antibodies for Identifying Immune Cell Types
The Bio-Techne family brands, R&D Systems and Novus Biologicals, are committed to providing the highest quality antibodies to support your research. Analyze the expression of immune checkpoint proteins or their ligands using our wide selection of flow cytometry-validated antibodies.